🇺🇸 FDA
Patent

US 11939383

B7-H4 antibodies and methods and use thereof

granted A61PA61P37/00

Quick answer

US patent 11939383 (B7-H4 antibodies and methods and use thereof) held by Five Prime Therapeutics, Inc. expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Five Prime Therapeutics, Inc.
Grant date
Tue Mar 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61P, A61P37/00